Equities

BrightPath Biotherapeutics Co Ltd

4594:TYO

BrightPath Biotherapeutics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)54.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.69m
  • 1 Year change-45.45%
  • Beta1.2376
Data delayed at least 20 minutes, as of Nov 22 2024 05:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year BrightPath Biotherapeutics Co Ltd had revenues fall -98.64% from 5.28m to 72.00k, though the company grew net income from a loss of 1.49bn to a smaller loss of 1.17bn.
Gross margin75.00%
Net profit margin-1,372,495.00%
Operating margin-1,365,446.00%
Return on assets-80.63%
Return on equity-102.58%
Return on investment-97.29%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at BrightPath Biotherapeutics Co Ltd fell by 473.61m. Cash Flow from Financing totalled 690.96m or 959,665.28% of revenues. In addition the company used 1.16bn for operations while cash used for investing totalled 7.65m.
Cash flow per share-16.32
Price/Cash flow per share--
Book value per share14.73
Tangible book value per share14.73
More ▼

Balance sheet in JPYView more

BrightPath Biotherapeutics Co Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio4.14
Quick ratio--
Total debt/total equity0.2634
Total debt/total capital0.2085
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.